Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents
نویسندگان
چکیده
منابع مشابه
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.
BACKGROUND New-generation coronary stents that release zotarolimus or everolimus have been shown to reduce the risk of restenosis. However, it is unclear whether there are differences in efficacy and safety between the two types of stents on the basis of prospectively adjudicated end points endorsed by the Food and Drug Administration. METHODS In this multicenter, noninferiority trial with mi...
متن کاملEverolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials
Background. Individual randomized trials have suggested that everolimus-eluting stents may have improved clinical outcomes compared to paclitaxel-eluting stents, but individual trials are underpowered to examine outcomes such as mortality and very late stent thrombosis. Methods. Medline, Cochrane, and conference proceedings were searched for randomized trials comparing everolimus versus paclita...
متن کاملEverolimus-eluting coronary stents
Bare metal stents enabled a reduction in the risk of early procedural complications and restenosis in comparison with balloon angioplasty alone, but introduced a new and device-specific iatrogenic condition, ie, in-stent restenosis due to increased neointimal hyperplasia. Sirolimus- and paclitaxel-eluting stents reduce restenosis and the need for new revascularizations in comparison with bare m...
متن کاملComparison of Everolimus-Eluting and Sirolimus-Eluting Coronary Stents: 1-Year Outcomes from the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial (RESET) Running title: Kimura et al.; Everolimus-eluting versus Sirolimus-eluting stents
Takeshi Kimura, MD; Takeshi Morimoto, MD; Masahiro Natsuaki, MD; Hiroki Shiomi, MD; Keiichi Igarashi, MD; Kazushige Kadota, MD; Kengo Tanabe, MD; Yoshihiro Morino, MD; Takashi Akasaka, MD; Yoshiki Takatsu, MD; Hideo Nishikawa, MD; Yoshito Yamamoto, MD; Yoshihisa Nakagawa, MD; Yasuhiko Hayashi, MD; Masashi Iwabuchi, MD; Hisashi Umeda, MD; Kazuya Kawai, MD; Hisayuki Okada, MD; Kazuo Kimura, MD; C...
متن کاملComparison of Everolimus- and Biolimus-Eluting Coronary Stents With€Everolimus-Eluting Bioresorbable Vascular Scaffolds
Fro ini Du an res da Bio (CR Lis Yo Ma BACKGROUND The first CE-approved bioresorbable vascular scaffold (BVS) is effective at treating simple lesions and stable coronary artery disease, but it has yet to be assessed versus the best-in-class drug-eluting stents (DES). OBJECTIVES This study sought to compare the performance of a BVS with that of everolimus-eluting stents (EES) and biolimus-elutin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation
سال: 2009
ISSN: 0009-7322,1524-4539
DOI: 10.1161/circulationaha.108.803528